{"id":"live-attenuated-chikv-vaccine-vla1553","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing a weakened form of the Chikungunya virus to stimulate an immune response.","oneSentence":"Live-attenuated CHIKV vaccine targets the Chikungunya virus","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:43:30.486Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chikungunya"}]},"trialDetails":[{"nctId":"NCT07414524","phase":"","title":"VLA1553-403 Pregnancy Surveillance Study","status":"NOT_YET_RECRUITING","sponsor":"Valneva Austria GmbH","startDate":"2026-03-31","conditions":"Chikungunya Virus Infection","enrollment":200},{"nctId":"NCT07254702","phase":"","title":"Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil","status":"ENROLLING_BY_INVITATION","sponsor":"Valneva Austria GmbH","startDate":"2026-02-02","conditions":"Chikungunya Virus Infection","enrollment":5000},{"nctId":"NCT07163845","phase":"","title":"Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil","status":"ACTIVE_NOT_RECRUITING","sponsor":"Valneva Austria GmbH","startDate":"2025-09-22","conditions":"Chikungunya Virus Infection","enrollment":5354},{"nctId":"NCT07347002","phase":"","title":"Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil","status":"ENROLLING_BY_INVITATION","sponsor":"Valneva Austria GmbH","startDate":"2026-02-02","conditions":"Chikungunya Virus Infection","enrollment":1200},{"nctId":"NCT04786444","phase":"PHASE3","title":"Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-02-22","conditions":"Chikungunya Virus Infection","enrollment":409},{"nctId":"NCT04546724","phase":"PHASE3","title":"Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2020-09-17","conditions":"Chikungunya Virus Infection","enrollment":4128},{"nctId":"NCT03382964","phase":"PHASE1","title":"Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2018-03-05","conditions":"Chikungunya","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Live-attenuated CHIKV vaccine VLA1553","genericName":"Live-attenuated CHIKV vaccine VLA1553","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"Live-attenuated CHIKV vaccine targets the Chikungunya virus Used for Chikungunya.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}